FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979754410> ?p ?o ?g. }

• W2979754410 endingPage "1542" @default.
• W2979754410 startingPage "1542" @default.
• W2979754410 abstract "Abstract Introduction: Congenital human blood coagulation factor XI (FXI) deficiency is associated with bleeding that is less severe than that observed in patients with other coagulation factor deficiencies, whereas severe FXI deficiency confers the decreased risk of deep vein thrombosis. FXI knockout mice show a reduction in venous thrombus formation with no bleeding. Therefore, FXI is considered to be a promising drug target for treatment and prevention of venous thromboembolism without increasing bleeding risk. Recently, we discovered a novel, potent, selective and injectable small molecule inhibitor of activated FXI (FXIa), ONO-IG-012, and evaluated the in vitro and in vivo pharmacological profiles of the compound. Methods: In anin vitro study, inhibitory effects of ONO-IG-012 on enzyme activities of human FXIa, other blood coagulation factors, and fibrinolytic factors were evaluated. Anticoagulant effects of ONO-IG-012 were also evaluated in human and rabbit plasma. In in vivo studies, the antithrombotic and hemorrhagic effects of ONO-IG-012 were compared to those of enoxaparin in rabbit models of deep venous thrombosis and femur hemorrhage. In the thrombosis model, under ketamine and xylazine anesthesia, inferior vena cava was isolated and partially ligated to reduce blood flow. The vein at the distal site was wrapped with filter paper saturated with ferric chloride (FeCl3) solution for 15 minutes to induce endothelial injury and subsequent thrombus formation. Sixty minutes after the application of FeCl3, the thrombus wet weight was measured. In the bleeding model, a puncture wound was made into the medullary canal at the epiphysis of femur using a drill under isoflurane anesthesia and mechanical ventilation. Blood was continuously collected with absorbent cotton for one hour, and the blood loss volume was calculated from its specific gravity. Intravenous administration of ONO-IG-012 or enoxaparin was initiated as a loading dose an hour before applying FeCl3 or producing a puncture wound, followed by their maintenance dose infusion. Blood was collected to measure APTT and PT just before the administration of the compounds and applying FeCl3 or producing a puncture wound. Results: ONO-IG-012 competitively inhibited human FXIa with a Ki value of 0.0019 μmol/L. Although ONO-IG-012 moderately inhibited human plasma kallikrein with a Ki value of 0.15 μmol/L, it had little effect on other human blood coagulation factors, and fibrinolytic factors [thrombin, FVIIa, FIXa, FXa, FXIIa, tPA, urokinase, and plasmin (Ki value >100 μmol/L)]. ONO-IG-012 prolonged APTT, and the concentration required to double the APTT was 0.098 μmol/L in human plasma and 0.30 μmol/L in rabbit plasma. However, prolongation of PT was not observed even at 33 μmol/L. ONO-IG-012 inhibited thrombus formation even at a dose as low as 0.1 mg/kg/h and achieved maximum antithrombotic effect at greater than or equal to 0.3 mg/kg/h. The ex vivo APTT was increased from baseline by 1.7 ± 0.0-fold at 0.1 mg/kg/h, by 2.8 ± 0.3-fold at 0.3 mg/kg/h, and by 5.4 ± 0.4-fold at 1 mg/kg/h, while PT showed no changes at any of the concentrations tested. Enoxaparin also inhibited thrombus formation at a dose of 10 IU/kg/h, and the antithrombotic effect at 30 IU/kg/h was comparable to that of ONO-IG-012 at 0.3 mg/kg/h (−87% vs. −80%). ONO-IG-012 did not affect the blood loss volume at all even at 10 mg/kg/h, which is 33-fold higher than the dose showing maximum antithrombotic effect (0.3 mg/kg/h). At 10 mg/kg/h, the blood loss volume was 0.7 ± 0.1 mL which is not statistically significant as compared to 1.2 ± 0.3 mL in the vehicle group, and the APTT ratio was 9.0 ± 1.1-fold. In contrast, enoxaparin increased the blood loss volume dose-dependently with the values of 4.5 ± 1.8 mL (not statistically significant) at 10 IU/kg/h, 8.4 ± 2.2 mL (P <0.01) at 30 IU/kg/h, and 23.1 ± 5.0 mL (P <0.001) at 100 IU/kg/h. Conclusions: ONO-IG-012 demonstrated a competitive, highly selective and potent inhibitory effect on FXIa among proteases involved in blood coagulation or fibrinolysis and a potent anticoagulant effect on APTT. ONO-IG-012 did not affect the blood loss volume at all even at 33-fold higher dose than the dose showing the maximum antithrombotic effect comparable to enoxaparin. ONO-IG-012 is expected to be a novel potent anticoagulant without an increased risk of bleeding for the treatment and prevention of venous thromboembolism. Disclosures No relevant conflicts of interest to declare." @default.
• W2979754410 created "2019-10-18" @default.
• W2979754410 creator A5000360403 @default.
• W2979754410 creator A5011671437 @default.
• W2979754410 creator A5014149299 @default.
• W2979754410 creator A5015106851 @default.
• W2979754410 creator A5020982275 @default.
• W2979754410 creator A5043387515 @default.
• W2979754410 creator A5048904122 @default.
• W2979754410 creator A5053597343 @default.
• W2979754410 creator A5055593891 @default.
• W2979754410 creator A5062412353 @default.
• W2979754410 creator A5074527700 @default.
• W2979754410 creator A5079501191 @default.
• W2979754410 creator A5082094505 @default.
• W2979754410 creator A5086469886 @default.
• W2979754410 date "2014-12-06" @default.
• W2979754410 modified "2023-10-16" @default.
• W2979754410 title "Discovery of a Novel, Potent, Selective and Injectable Small Molecule Inhibitor of Blood Coagulation Factor XIa, ONO-8610539: in Vitro and in Vivo Pharmacological Profiles" @default.
• W2979754410 doi "https://doi.org/10.1182/blood.v124.21.1542.1542" @default.
• W2979754410 hasPublicationYear "2014" @default.
• W2979754410 type Work @default.
• W2979754410 sameAs 2979754410 @default.
• W2979754410 citedByCount "2" @default.
• W2979754410 countsByYear W29797544102018 @default.
• W2979754410 countsByYear W29797544102021 @default.
• W2979754410 crossrefType "journal-article" @default.
• W2979754410 hasAuthorship W2979754410A5000360403 @default.
• W2979754410 hasAuthorship W2979754410A5011671437 @default.
• W2979754410 hasAuthorship W2979754410A5014149299 @default.
• W2979754410 hasAuthorship W2979754410A5015106851 @default.
• W2979754410 hasAuthorship W2979754410A5020982275 @default.
• W2979754410 hasAuthorship W2979754410A5043387515 @default.
• W2979754410 hasAuthorship W2979754410A5048904122 @default.
• W2979754410 hasAuthorship W2979754410A5053597343 @default.
• W2979754410 hasAuthorship W2979754410A5055593891 @default.
• W2979754410 hasAuthorship W2979754410A5062412353 @default.
• W2979754410 hasAuthorship W2979754410A5074527700 @default.
• W2979754410 hasAuthorship W2979754410A5079501191 @default.
• W2979754410 hasAuthorship W2979754410A5082094505 @default.
• W2979754410 hasAuthorship W2979754410A5086469886 @default.
• W2979754410 hasConcept C126322002 @default.
• W2979754410 hasConcept C150903083 @default.
• W2979754410 hasConcept C207001950 @default.
• W2979754410 hasConcept C2778382381 @default.
• W2979754410 hasConcept C2780011451 @default.
• W2979754410 hasConcept C2780868729 @default.
• W2979754410 hasConcept C2781362458 @default.
• W2979754410 hasConcept C2910216633 @default.
• W2979754410 hasConcept C42219234 @default.
• W2979754410 hasConcept C71924100 @default.
• W2979754410 hasConcept C86803240 @default.
• W2979754410 hasConcept C98274493 @default.
• W2979754410 hasConceptScore W2979754410C126322002 @default.
• W2979754410 hasConceptScore W2979754410C150903083 @default.
• W2979754410 hasConceptScore W2979754410C207001950 @default.
• W2979754410 hasConceptScore W2979754410C2778382381 @default.
• W2979754410 hasConceptScore W2979754410C2780011451 @default.
• W2979754410 hasConceptScore W2979754410C2780868729 @default.
• W2979754410 hasConceptScore W2979754410C2781362458 @default.
• W2979754410 hasConceptScore W2979754410C2910216633 @default.
• W2979754410 hasConceptScore W2979754410C42219234 @default.
• W2979754410 hasConceptScore W2979754410C71924100 @default.
• W2979754410 hasConceptScore W2979754410C86803240 @default.
• W2979754410 hasConceptScore W2979754410C98274493 @default.
• W2979754410 hasIssue "21" @default.
• W2979754410 hasLocation W29797544101 @default.
• W2979754410 hasOpenAccess W2979754410 @default.
• W2979754410 hasPrimaryLocation W29797544101 @default.
• W2979754410 hasRelatedWork W1994594138 @default.
• W2979754410 hasRelatedWork W2027144270 @default.
• W2979754410 hasRelatedWork W2032613738 @default.
• W2979754410 hasRelatedWork W2095080508 @default.
• W2979754410 hasRelatedWork W2345144434 @default.
• W2979754410 hasRelatedWork W2552243206 @default.
• W2979754410 hasRelatedWork W2772351616 @default.
• W2979754410 hasRelatedWork W3030770615 @default.
• W2979754410 hasRelatedWork W3111527613 @default.
• W2979754410 hasRelatedWork W2184151832 @default.
• W2979754410 hasVolume "124" @default.
• W2979754410 isParatext "false" @default.
• W2979754410 isRetracted "false" @default.
• W2979754410 magId "2979754410" @default.
• W2979754410 workType "article" @default.